Gapping up
In reaction to earnings/guidance:
- TSEM +15.1%, CVNA +12.7% (guidance update), YOU +2.9%, FFIE +2.4%, BOC +1.6%
Other news:
- SAVE +15.8% (JetBlue Urges Spirit Shareholders to Protect Their Interests and ‘Vote No' on Frontier Transaction at Upcoming Spirit Special Meeting)
- SCPH +14% (announces FDA acceptance of FUROSCIX new drug application)
- RTLR +12.5% (Diamondback Energy (FANG) agrees to acquire publicly held units of Rattler Midstream)
- TVTX +8.2% (FDA accepts Priority Review of NDA under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy)
- HEAR +5.6% (announces agreement with The Donerail Group to refresh its Board of Directors and provides additional detail regarding ongoing, robust alternatives process)
- STRY +4.9% (new Soros Fund holding)
- RCKT +4.5% (presents "positive" clinical data from danon disease, fanconi anemia and pyruvate kinase deficiency programs)
- KMPH +2.2% (announces strategic acquisition of Arimoclomol from Orphazyme)
- KSS +1.1% (new Starboard Value position)
- CXW +1% (approved a share repurchase program authorizing the Company to repurchase up to $150 million of the Company's common stock)
Analyst comments:
- SOFI +4.4% (upgraded to Overweight from Neutral at Piper Sandler)
- PDD +2.1% (upgraded to Overweight from Underweight at JP Morgan)
- RKT +2.1% (upgraded to Mkt Perform from Underperform at Keefe Bruyette)
- SHAK +1.9% (upgraded to Buy from Neutral at Northcoast)
- NFLX +1.8% (upgraded to Outperform from Neutral at Wedbush)